Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy
- PMID: 32220112
- PMCID: PMC9906401
- DOI: 10.1111/jth.14817
Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy
Abstract
Background: A relatively high mortality of severe coronavirus disease 2019 (COVID-19) is worrying, and the application of heparin in COVID-19 has been recommended by some expert consensus because of the risk of disseminated intravascular coagulation and venous thromboembolism. However, its efficacy remains to be validated.
Methods: Coagulation results, medications, and outcomes of consecutive patients being classified as having severe COVID-19 in Tongji hospital were retrospectively analyzed. The 28-day mortality between heparin users and nonusers were compared, as was a different risk of coagulopathy, which was stratified by the sepsis-induced coagulopathy (SIC) score or D-dimer result.
Results: There were 449 patients with severe COVID-19 enrolled into the study, 99 of them received heparin (mainly with low molecular weight heparin) for 7 days or longer. D-dimer, prothrombin time, and age were positively, and platelet count was negatively, correlated with 28-day mortality in multivariate analysis. No difference in 28-day mortality was found between heparin users and nonusers (30.3% vs 29.7%, P = .910). But the 28-day mortality of heparin users was lower than nonusers in patients with SIC score ≥4 (40.0% vs 64.2%, P = .029), or D-dimer >6-fold of upper limit of normal (32.8% vs 52.4%, P = .017).
Conclusions: Anticoagulant therapy mainly with low molecular weight heparin appears to be associated with better prognosis in severe COVID-19 patients meeting SIC criteria or with markedly elevated D-dimer.
Keywords: D-dimer; coagulopathy; coronavirus disease 2019; low molecular weight heparin; sepsis.
© 2020 International Society on Thrombosis and Haemostasis.
Figures
Comment in
-
The versatile heparin in COVID-19.J Thromb Haemost. 2020 May;18(5):1020-1022. doi: 10.1111/jth.14821. Epub 2020 Apr 27. J Thromb Haemost. 2020. PMID: 32239799 Free PMC article. No abstract available.
-
Venous thromboembolism in COVID-19 patients.J Thromb Haemost. 2020 Jun;18(6):1516-1517. doi: 10.1111/jth.14842. J Thromb Haemost. 2020. PMID: 32294289 Free PMC article. No abstract available.
-
Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19.J Thromb Haemost. 2020 Jun;18(6):1517-1519. doi: 10.1111/jth.14844. J Thromb Haemost. 2020. PMID: 32294295 Free PMC article. No abstract available.
-
Reply to "Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy".J Thromb Haemost. 2020 Jun;18(6):1519-1520. doi: 10.1111/jth.14852. Epub 2020 May 6. J Thromb Haemost. 2020. PMID: 32302445 Free PMC article. No abstract available.
-
Response to 'Reply to Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy'.J Thromb Haemost. 2020 Jun;18(6):1520-1521. doi: 10.1111/jth.14851. Epub 2020 May 6. J Thromb Haemost. 2020. PMID: 32302451 Free PMC article. No abstract available.
-
Potential of heparin and nafamostat combination therapy for COVID-19.J Thromb Haemost. 2020 Jun;18(6):1521-1522. doi: 10.1111/jth.14858. Epub 2020 May 6. J Thromb Haemost. 2020. PMID: 32302456 Free PMC article. No abstract available.
-
Inaccurate conclusions by Tang and colleagues.J Thromb Haemost. 2020 Jul;18(7):1797. doi: 10.1111/jth.14857. Epub 2020 May 26. J Thromb Haemost. 2020. PMID: 32304156 Free PMC article. No abstract available.
-
Response to 'Inaccurate conclusions by Tang and colleagues'.J Thromb Haemost. 2020 Jul;18(7):1798. doi: 10.1111/jth.14862. Epub 2020 May 6. J Thromb Haemost. 2020. PMID: 32311835 Free PMC article. No abstract available.
-
The tug-of-war between coagulopathy and anticoagulant agents in patients with COVID-19.Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):262-264. doi: 10.1093/ehjcvp/pvaa048. Eur Heart J Cardiovasc Pharmacother. 2020. PMID: 32383737 Free PMC article. No abstract available.
-
Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID-19 patients.J Thromb Haemost. 2020 Aug;18(8):2073-2075. doi: 10.1111/jth.14902. J Thromb Haemost. 2020. PMID: 32408391 Free PMC article. No abstract available.
-
COVID-19, thromboembolic risk and thromboprophylaxis: learning lessons from the bedside, awaiting evidence.Blood Transfus. 2020 May;18(3):226-229. doi: 10.2450/2020.0113-20. Blood Transfus. 2020. PMID: 32453688 Free PMC article. No abstract available.
-
Sars-CoV-2 Induced Coagulopathy and Prognosis in Hospitalized Patients: A Snapshot from Italy.Thromb Haemost. 2020 Aug;120(8):1233-1236. doi: 10.1055/s-0040-1712918. Epub 2020 May 26. Thromb Haemost. 2020. PMID: 32455440 No abstract available.
-
Major cardiovascular events in patients with Coronavirus Disease 2019: Experience of a cardiovascular department of Northern Italy.Thromb Res. 2021 Jan;197:202-204. doi: 10.1016/j.thromres.2020.10.038. Epub 2020 Nov 6. Thromb Res. 2021. PMID: 33260043 Free PMC article.
Similar articles
-
Risk Benefit Analysis in Reference to use of LMWH in COVID-19.J Assoc Physicians India. 2020 Sep;68(9):52-61. J Assoc Physicians India. 2020. PMID: 32798346
-
COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation.Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620938149. doi: 10.1177/1076029620938149. Clin Appl Thromb Hemost. 2020. PMID: 32677459 Free PMC article. Review.
-
Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study.Lancet Haematol. 2020 Sep;7(9):e671-e678. doi: 10.1016/S2352-3026(20)30217-9. Epub 2020 Jul 10. Lancet Haematol. 2020. PMID: 32659214 Free PMC article.
-
Coagulopathy of Coronavirus Disease 2019.Crit Care Med. 2020 Sep;48(9):1358-1364. doi: 10.1097/CCM.0000000000004458. Crit Care Med. 2020. PMID: 32467443 Free PMC article. Review.
-
Coagulation abnormalities and thrombosis in patients with COVID-19.Lancet Haematol. 2020 Jun;7(6):e438-e440. doi: 10.1016/S2352-3026(20)30145-9. Epub 2020 May 11. Lancet Haematol. 2020. PMID: 32407672 Free PMC article. No abstract available.
Cited by
-
Intravenous high-dose anakinra drops venous thrombosis and acute coronary syndrome in severe and critical COVID-19 patients: a propensity score matched study.Sci Rep. 2024 May 29;14(1):12369. doi: 10.1038/s41598-024-62079-y. Sci Rep. 2024. PMID: 38811592 Free PMC article.
-
Bleeding and thrombotic events and intensity of heparin therapy in the two first waves of COVID-19.Intern Emerg Med. 2024 May 18. doi: 10.1007/s11739-024-03635-2. Online ahead of print. Intern Emerg Med. 2024. PMID: 38761332
-
Time to maximum amplitude of thromboelastography can predict mortality in patients with severe COVID-19: a retrospective observational study.Front Med (Lausanne). 2024 May 2;11:1356283. doi: 10.3389/fmed.2024.1356283. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38756947 Free PMC article.
-
A systematic review of thromboembolic complications and outcomes in hospitalised COVID-19 patients.BMC Infect Dis. 2024 May 10;24(1):484. doi: 10.1186/s12879-024-09374-1. BMC Infect Dis. 2024. PMID: 38730292 Free PMC article.
-
COVID-Induced Thrombotic Thrombocytopenic Purpura: A Case Report and Treatment-Focused Review.Cureus. 2024 Mar 30;16(3):e57252. doi: 10.7759/cureus.57252. eCollection 2024 Mar. Cureus. 2024. PMID: 38686279 Free PMC article.
References
-
- Shanghai Clinical Treatment Expert Group for. COVID‐19 Comprehensive treatment and management of coronavirus disease 2019: expert consensus statement from Shanghai (in Chinese) Chin J Infect Dis. 2020;38 doi: 10.3760/cma.j.issn.1000-6680.2020.0016. - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical